You just read:

Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-Term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive CGRP-Targeting Monoclonal Antibodies

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

May 07, 2019, 23:30 ET